Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 1;33(3):201-207.
doi: 10.3344/kjp.2020.33.3.201.

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

Grisuna Singh  1   2 , Sejin Song  2 , Eunjoo Choi  2 , Pyung-Bok Lee  2   3 , Francis Sahngun Nahm  2   3
Affiliations
Review

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

Grisuna Singh et al. Korean J Pain. .

Abstract

Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines and discusses the advantage of RZV over LZV based on the available literature.

Keywords: Attenuated; Herpes Zoster; Herpes Zoster Vaccine; Humoral; Immunity; Neuralgia; Pain; Postherpetic; Subunit; Synthetic.; Vaccines.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

References

    1. Jeon YH. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain. 2015;28:177–84. doi: 10.3344/kjp.2015.28.3.177. - DOI - PMC - PubMed
    1. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342:635–45. doi: 10.1056/NEJM200003023420906. - DOI - PubMed
    1. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371:1526–33. doi: 10.1056/NEJMcp1403062. - DOI - PubMed
    1. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016. doi: 10.1038/nrdp.2015.16. - DOI - PMC - PubMed
    1. Shrestha M, Chen A. Modalities in managing postherpetic neuralgia. Korean J Pain. 2018;31:235–43. doi: 10.3344/kjp.2018.31.4.235. - DOI - PMC - PubMed

LinkOut - more resources